logo
Wrong email address or username
Wrong email address or username
Incorrect verification code
back to top
Search tags: drug-use
Load new posts () and activity
Like Reblog Comment
show activity (+)
review 2018-05-31 01:47
Does the Noise in my Head Bother You?
Does the Noise in My Head Bother You? - Steven Tyler

So, I actually finished it.  I know, I'm a glutton for punishment.  I just wanted to count it toward my reading goal since I had already read half of it.  I gave it 2 stars instead of 1 because I actually finished it.  If I hadn't been able to finish it and it ended up in the trash, or the street (close) I would have given it only one star.  

 

---------------------------

 

Terrible.  So I knew they were crazy, did a lot of drugs and I assumed a lot of crazy sex but I didn't not expect that to be pretty much the whole book.  I did enjoy the first few chapters about his childhood.  I looked up the people and songs he mentioned and listened to some of them online.  Then, he starts talking about doing drugs and sex and fighting with his band mates and he sounded like a whiny child.  He truly only thinks about himself and justifies his actions while at the same time acknowledging he was wrong and sorry.  This book was a rambling mess and unfortunately there are things you can't unknow.

 

Omg, so I was reading reviews other people wrote and this one is so funny because it is exactly what I was thinking.  Only this person writes it like a letter to Steven Tyler.  

Review by Jennifer

Like Reblog Comment
show activity (+)
text 2018-05-29 21:00
Reading progress update: I've read 170 out of 390 pages.
Does the Noise in My Head Bother You? - Steven Tyler

Terrible.... complete waste of time.  

 

I was hoping for some cool music stuff but I only semi-enjoyed the first chapter or two about his childhood.  I finally looked up the audio book and let it play while I did other things.  It is not really worth any time and some of the stuff I've heard I'll never be able to unknow.  I'll probably just flip through the rest looking for anything worth my time.  

Like Reblog Comment
text 2018-05-28 13:31
Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Overview:

Acute Lymphoblastic Leukemia is a type of cancer which affects white blood cells. It is also called as Acute lymphocytic leukemia. IALL progresses rapidly without treatment. Acute lymphoblastic leukemia (ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. Symptoms of ALL includes fever, anemia, bleeding, blood clots, bone pain, rashes on skin, Palpable lymphadenopathy etc.

ALL is diagnosed by coagulation studies, blood tests, X-Ray, CT-Scan, ECG, MRI, bone marrow aspiration and biopsy etc. Treatment of ALL includes induction chemotherapy, consolidation chemotherapy, Stem cell transplantation and others.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

 

Segmentation:

By Trial Phase, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:

  • Novartis
  • Pfizer
  • Ariad Pharmaceuticals
  • Juno Therapeutics
  • Janssen
  • Amgen
  • (Erytech Pharma
  • Bristol-Myers Squibb
  • Others

By Drugs, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:

  • Blinatumomab
  • Carfilzomib
  • calaspargasepegol
  • Dasatinib
  • Ibrutinib
  • Inotuzumabozogamicin
  • Ofatumumab
  • Ponatinib
  • Others

By Route of Administration, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:

  • Oral
  • Parenteral

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu

 

 

Space Analysis:

  • In October 2015, Seattle Genetics, Inc.initiated randomized phase II clinical trial of denintuzumabmafodotin (SGN-CD19A) in combination with second-line salvage regimen of rituximab (Rituxan), ifosfamide, carboplatin and etoposide (RICE), for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
  • In September 2017, Kiadis pharma’s ATR101 was granted Regenerative Medicine Advanced Therapy (RMAT) designation by U.S.FDA and in April 2017, Kiadis pharma received regulatory approval from the national authority in Belgium to start pivotal Phase III trial with ATIR101™ and from the national authority in Germany to start the Phase I/II trial with ATIR201 for patients suffering from blood cancers

 

Report Description:

Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Acute Lymphoblastic Leukemia treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Acute Lymphoblastic Leukemia disease pipeline drugs development. This report studies the dynamics of the Acute Lymphoblastic Leukemia Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Acute Lymphoblastic Leukemia disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/

About Precision Business Insights

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

 

Contact to Precision Business Insights,

 

Kemp House,

152 – 160 City Road,

London EC1V 2NX

 

Email: sales@precisionbusinessinsights.com

 

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

 

Like Reblog Comment
review 2018-05-01 07:50
Therapeutic Drug Monitoring Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Global Therapeutic Drug Monitoring Market: By Product (Equipment (Proteomics Equipment, Immuno Assay Analysers and Others) and Consumables), By Drug class (Antibiotics, Immunosuppressant’s, Anti-Epileptic Drugs, Psychoactive Drugs, Anti-Arrhythmic Drugs and Others), By end user (Hospitals, Clinical Laboratories and Others) By Geography – Therapeutic Drug Monitoring Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

 

Market Outline: Global Therapeutic Drug Monitoring Market

Therapeutic drug monitoring refers to the monitoring of drug concentrations in the body fluids, usually plasma, during the treatment or diagnosis of the condition or disease. The therapeutic drug monitoring is done for the specific drugs only because many drugs are not clearly related to their effects. The therapeutic drug monitoring aims to reduce the toxicity assisted with diagnosis or helps to enhance the drug efficiency. Some of the drugs have narrow therapeutic window. If the concentration is above the upper limit, it shows toxic effects. If the drug is below the lower level, it will not show therapeutic effect. Especially, for these type of drugs, therapeutic drug monitoring is used. Therapeutic drug monitoring helps the physicians to optimise the drug for getting the therapeutic outcome.

 

Market dynamics: Global Therapeutic Drug Monitoring Market

Global therapeutic drug monitoring is mainly driven by the rise in demand for the administration of personalized dosage of the medicine and technological advancements in tests that are used to monitor the drug therapeutics. In addition, prevalence of the psychiatric diseases and cancer which need the drug monitoring for the optimum therapeutic outcomes and advantages such as dose optimisation and applications in personalized medicine expected to boost the therapeutic drug monitoring market over the forecast period. Furthermore, advent of biomarker identification for cancer diagnostics expected to benefit the growth of global therapeutic drug monitoring market. However, high costs and lack of skilled professionals may hamper the global therapeutic drug monitoring market over coming years.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-therapeutic-drug-monitoring-market/#ulp-4H8Z4LpNMLEuOnnx

 

Market Scope: Global Therapeutic Drug Monitoring Market

Global Therapeutic Drug Monitoring market is segmented based on products, drug class, and end user

Based on product, global therapeutic drug monitoring market is segmented into

  • Equipment
    • Proteomics Equipment
    • Immuno Assay Analysers
    • Others
  • Consumables

Based on drug class, global therapeutic drug monitoring market is segmented into

  • Antibiotics
  • Immunosuppressant’s
  • Anti-Epileptic Drugs
  • Psychoactive Drugs
  • Anti-Arrhythmic Drugs
  • Others

Based on end user, global therapeutic drug monitoring market is segmented into

  • Hospitals
  • Clinical Laboratories
  • Others

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-therapeutic-drug-monitoring-market/#ulp-c654SbFYO64MsOhu

 

Market Summary: Global Therapeutic Drug Monitoring Market

Global therapeutic drug monitoring devices market expected to grow at significant rates owing to the rise in prevalence of neuronal disorders and cancers worldwide. According to World Health Organization (WHO), about 50 Mn people have epilepsy worldwide and 80% of people from low and middle-income countries. Companies operating in global therapeutic monitoring market are developing new innovative products and gaining the competitive advantage. For instance, in September 2012, Bruker Corporation launched Toxtyper, an automated clinical spectroscopy solution for toxicology laboratories in Europe. Toxtyper is faster and reliable solution for the toxics and abusive drug monitoring. Furthermore, companies are adopting the merger and acquisition strategies to strengthen its product portfolio and increase their market position.

 

Regional Analysis: Global Therapeutic Drug Monitoring Market

Geographically therapeutic drug monitoring market is divided into five key regions, i.e. North America, Europe, Asia- Pacific, Latin America, and The Middle East & Africa. North America expected to have the major market share in global therapeutic drug monitoring owing to the rise in demand for metabolomics studies and high rate of organ transplantation. In addition, growth in the pharmacodynamics and kinetic studies for the dosage optimisation and growth in demand for the personalized medicine expected to boost the North America therapeutic drug monitoring market over the forecast period. Asia Pacific is expected to have the rapid growth rate owing to developing healthcare infrastructure, rise in R&D investments. Europe therapeutic drug monitoring market expected to have notable growth rate over the coming years due to rise in demand for personalized medicine and presence of key market players in the region.

 

Competition Assessment: Global Therapeutic Drug Monitoring Market

Key player’s profiles in global therapeutic drug monitoring market include

  • Beckman Coulter Inc. (U.S.)
  • Hoffmann-La Roche (U.S.)
  • Bio-Rad Laboratories Inc. (U.S.)
  • Thermo Fisher Scientific (U.S.)
  • Siemens Healthineers (Siemens AG (Germany)
  • Alere Inc. (U.S.)
  • Diagnostics GmbH (Germany)
  • BÜHLMANN Laboratories AG (Germany)
  • bioMérieux (U.S.)
  • Merck Millipore (E. Merck KG) (Germany)
  • DiaSorin (Italy)
  • Myriad Genetics (U.S.)
  • Miraca Life Sciences (Miraca Holdings Inc.) (Japan)

 

Notable Market Developments: Global Therapeutic Drug Monitoring Market

  • In January 2016, BÜHLMANN launched Quantum Blue Infliximab trough level rapid test for plasma level monitoring of TNF-alpha monoclonal antibody for IBD patients.
  • In July 2015, Bio-Techne Corporation acquired Cliniqa Corporation to strengthen its portfolio and market position.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-therapeutic-drug-monitoring-market/#ulp-14mlyhjMGhVjZqa3

 

Key Features of the Report:

  • The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

 

 

Get access to full summary @

 

https://www.precisionbusinessinsights.com/market-reports/global-therapeutic-drug-monitoring-market/

About Precision Business Insights

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

 

Contact to Precision Business Insights,

 

Kemp House,

152 – 160 City Road,

London EC1V 2NX

 

Email: sales@precisionbusinessinsights.com

 

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

 

Source: www.precisionbusinessinsights.com/market-reports/global-therapeutic-drug-monitoring-market
More posts
Your Dashboard view:
Need help?